GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Cyclically Adjusted FCF per Share

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Cyclically Adjusted FCF per Share : $5.79 (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Taro Pharmaceutical Industries's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.095. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $5.79 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Taro Pharmaceutical Industries's average Cyclically Adjusted FCF Growth Rate was -8.20% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -4.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -0.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Taro Pharmaceutical Industries was 31.70% per year. The lowest was -4.80% per year. And the median was 7.75% per year.

As of today (2024-05-17), Taro Pharmaceutical Industries's current stock price is $42.30. Taro Pharmaceutical Industries's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $5.79. Taro Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF of today is 7.31.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Taro Pharmaceutical Industries was 37.12. The lowest was 3.84. And the median was 15.11.


Taro Pharmaceutical Industries Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Taro Pharmaceutical Industries's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Cyclically Adjusted FCF per Share Chart

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.95 7.34 7.42 6.67 6.33

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.31 6.33 6.23 6.12 5.79

Competitive Comparison of Taro Pharmaceutical Industries's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taro Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF falls into.



Taro Pharmaceutical Industries Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Taro Pharmaceutical Industries's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.095/129.4194*129.4194
=-0.095

Current CPI (Dec. 2023) = 129.4194.

Taro Pharmaceutical Industries Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 1.847 99.695 2.398
201406 0.695 100.560 0.894
201409 1.305 100.428 1.682
201412 2.176 99.070 2.843
201503 4.851 99.621 6.302
201506 1.538 100.684 1.977
201509 1.322 100.392 1.704
201512 2.428 99.792 3.149
201603 3.492 100.470 4.498
201606 1.104 101.688 1.405
201609 3.067 101.861 3.897
201612 2.946 101.863 3.743
201703 2.652 102.862 3.337
201706 1.631 103.349 2.042
201709 1.470 104.136 1.827
201712 2.024 104.011 2.518
201803 2.207 105.290 2.713
201806 1.944 106.317 2.366
201809 1.736 106.507 2.109
201812 2.531 105.998 3.090
201903 1.299 107.251 1.568
201906 1.936 108.070 2.318
201909 0.911 108.329 1.088
201912 2.388 108.420 2.851
202003 1.086 108.902 1.291
202006 1.540 108.767 1.832
202009 -3.034 109.815 -3.576
202012 0.982 109.897 1.156
202103 1.267 111.754 1.467
202106 1.060 114.631 1.197
202109 -1.437 115.734 -1.607
202112 -5.195 117.630 -5.716
202203 -1.618 121.301 -1.726
202206 -1.600 125.017 -1.656
202209 0.504 125.227 0.521
202212 0.132 125.222 0.136
202303 1.280 127.348 1.301
202306 0.025 128.729 0.025
202309 1.078 129.860 1.074
202312 -0.095 129.419 -0.095

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Taro Pharmaceutical Industries  (NYSE:TARO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Taro Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=42.30/5.79
=7.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Taro Pharmaceutical Industries was 37.12. The lowest was 3.84. And the median was 15.11.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Taro Pharmaceutical Industries Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro Achieves Global Resolution of DOJ Antitrust Investigations

By Business Wire Business Wire 07-24-2020

Taro to Announce First Quarter Results on July 29, 2020

By Business Wire Business Wire 07-22-2020

Taro to Release Third Quarter Results on January 24, 2023

By Business Wire Business Wire 01-19-2023

Taro Completes Acquisition of Alchemee

By Business Wire Business Wire 03-01-2022

Taro to Acquire Alchemee From Galderma

By Business Wire Business Wire 02-22-2022

Taro to Announce Third Quarter Results on January 27, 2022

By Business Wire Business Wire 01-21-2022